Available in Brazil, United States
This is a Phase III, multi-center, open-label, sponsor-blinded, randomized, global study
to assess the efficacy and safety of AZD0901 compared to Investigator's choice of therapy
as the 2L+ treatment for participants with advanced or metastatic gastric or GEJ
adenocarcinoma expressing CLDN18.2, and the clinical performance of the investigational
IVD. As part of this combined approach, the efficacy analyses from this study will also
provide the basis to evaluate the clinical performance of Ventana CLDN18.2 assay as an
IVD device for the identification of patients with advanced or metastatic gastric or GEJ
adenocarcinoma expressing CLDN18.2 who may benefit from AZD0901.
589Patients around the world